AI in Drug Development 🚀 5 Early Wins—Limits Revealed
Learn AI in drug development with Claude drug discovery—5 early wins and limits across AI life sciences, lab optimization, manufacturing & AI clinical trial planning.
How AI Is Starting to Change Drug Development
Drug development is often framed like it comes down to finding a promising molecule. In reality, molecules are only one piece of a long, expensive process. Researchers have to pick targets, test candidate designs, deal with manufacturing realities, prepare regulatory documents, and plan clinical trials. A delay - or a bad call - at any point can stall a program or end it altogether.
Anthropic's early work with Claude offers a good snapshot of where AI may help today, and where the evidence is still preliminary. The company describes partnerships across drug discovery, lab testing, manufacturing, company operations, and clinical planning, along with its own research into rare childhood diseases. Some projects report measurable gains in lab results or reduced time spent on paperwork. Still, none of this is strong proof that AI has produced a medicine that's been shown to work in people.
The question isn't whether AI can replace drug researchers. It's whether it can reduce specific bottlenecks while keeping decisions testable, accountable, and safe. This article looks at the projects that have been reported so far, what their results suggest, and what biotech teams should check before adopting similar systems.
Why is AI being applied across the drug development process?
A drug program is a chain of decisions and experiments - not a single act of invention. Teams have to figure out a disease mechanism worth pursuing, decide what kind of intervention could affect it, design and refine a candidate, and then show that it can be made consistently. Later, they package evidence for regulators and design trials that can answer whether the treatment is safe and effective.
Each stage has its own bottlenecks. A candidate can fail because it's unstable, hard to manufacture, or a poor fit for trial conditions. Even strong teams can lose time to documentation, review, and coordination. Fixing one part of the process doesn't automatically fix the rest.
That's why Anthropic says its strategy is to work across multiple stages and with organizations that already have active programs. The partnerships described include BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Anthropic also describes its own research program focused on rare forms of childhood muscular dystrophy.
The basic pitch is to use Claude as a tool for different tasks - generating candidate designs, interpreting experimental data, drafting documents, or helping assess development plans. That's broader than "ask a model to invent a drug." It also changes what "good results" look like. Design-generation work needs lab validation; document-review work needs a process that catches errors without drowning reviewers in noise.
For teams considering AI, a practical starting point is to map the development workflow and identify a bottleneck that's both costly and measurable. The right question often isn't "Where can we add AI?" It's "Which task consumes time or slows progress, and how will we know the model is actually improving it?" That keeps evaluation tied to real work, not flashy demos.
What do the early partner projects show?
These partner projects describe several different ways people are trying to use AI. Some focus on molecular designs; others use Claude for manufacturing records, internal workflows, or clinical planning. The results aren't directly comparable because the projects use different measures and sit at different points in development. Treat them as case studies for testing AI in real settings - not as one benchmark that "drug discovery AI" can be judged against.
Generate Biomedicines: redesigning part of a cell therapy
Generate Biomedicines is working to adapt CAR T-cell therapy - used historically against blood cancers - for solid tumors. The team wanted to shorten part of the therapy's genetic instructions to make room for additional instructions. Six Generate scientists used Claude Code to propose designs for that section.
In the reported lab tests, one design was about 70% shorter than the standard version. It was reported to help immune cells produce roughly 10 times as many receptors, improve tumor-cell killing, and stay active longer. Those are meaningful preclinical measurements, but they don't show the redesigned therapy will be safe and effective in patients. That still requires more development and clinical testing.
Divergence Labs: generating antibody designs for food allergies
Divergence Labs is exploring an approach to food allergies aimed at moving IgE off immune cells, not just neutralizing IgE in the blood. The intended drug has two functional parts: one to bind IgE and another to help remove it from the cell.
Claude translated the company's goals into a design plan and reportedly generated about 35,000 antibody designs in roughly a month. Early tests identified three designs that could bind IgE and 20 that could dislodge it. Three of the dislodging designs reportedly worked better than a standard medication used for comparison. The next step is combining the two functions into a single drug. A set of early "hits" is useful - but it's not a finished treatment.
BigHat Biosciences: improving candidate properties with lab feedback
BigHat pairs AI with an automated lab to optimize drug candidates. In this project, Claude worked with scientists on two antibody fragments: one aimed at cancer cells and another intended to help a drug stay in the body longer. The team focused on binding strength, heat stability, and a tendency to clump.
Connected to BigHat's Reccy lab data system, Claude proposed changes. The lab produced and tested about 1,010 variants over roughly 10 weeks. When the team suspected that common stability and clumping measures were misleading, Claude and an Anthropic researcher reanalyzed the raw data and proposed revised metrics and a protocol change. BigHat's scientists then refined and ran the tests, and the main predictions held.
The reported best versions bound more than 10 times as tightly as the originals. The cancer-targeting lead stayed in solution at a temperature 18°C higher, while the other lead clumped more than 100 times more slowly. The takeaway isn't just the numbers. AI's value here depends on a feedback loop with experiments you can trust - and on measurement choices that match what the team actually cares about.
Enveda: reducing documentation and regulatory drafting work
Enveda used Claude for manufacturing and regulatory tasks rather than molecule design. Manufacturing chemists often spend a lot of time preparing and reviewing records showing that each drug batch meets quality requirements. Enveda built a system that connected manufacturing documents to Claude so it could flag possible issues.
Across 1,061 pages, Claude reportedly found all 11 issues identified by human reviewers and flagged seven additional ones. The process reduced human review time by 89%, from more than 25 hours to under three. Claude also drafted two regulatory documents. One first draft reportedly took four hours instead of an estimated three months of manual work, and Enveda's usual review process found one minor error in the other document.
These results point to a potentially useful role for AI in high-volume, structured review. But they don't eliminate the need for qualified reviewers, and they don't prove that every document type can be handled the same way. In regulated work, speed only matters if traceability and quality stay intact.
How could AI change biotech economics and operations?
These projects raise a bigger business question: can AI lower the cost and coordination burden of running drug programs enough to make more difficult research viable? Drug discovery is slow and failure-prone. When capital is tight, investors may prefer projects with clearer precedent rather than riskier work aimed at larger unmet needs. Lowering the cost of testing an idea could shift those calculations, even though it can't remove biological uncertainty.
The Column Group is working with Anthropic to build Pleiades, a company aimed at running more complex drug programs than a small team typically could. Early work includes tools and workflows for Claude. The company evaluated its first Claude skill - designed to help assess whether targets are worth pursuing - across 45 target-disease pairs. That's an initial evaluation, not proof that the overall company model will succeed. The real test is whether the workflow makes good decisions consistently and whether those decisions lead to viable programs.
Anthropic has also begun working with Bristol Myers Squibb on clinical trial planning. BMS says it uses Claude to assess plans for an early-stage drug and estimate the likelihood of trial success. The company reported that Claude produced a useful initial analysis from a single prompt, helping inform development options that would otherwise take days to evaluate. The organizations say they plan to expand the work in 2027 to explore potential in early development. This is decision support, not an automated verdict on whether a trial should proceed.
Anthropic's own program is another operational example. The company acquired Mithril Medicine, a one-person company founded by Cody Tranbarger, focused on treatments for two rare forms of muscular dystrophy. Tranbarger reportedly used Claude to organize contracts, coordinate logistics and experiments with 11 external laboratories, and handle other operational work. The source reports that a possible treatment for one form moved from an idea to promising mouse results in under 18 months. Anthropic says it expects a candidate could be ready to enter human trials as soon as late 2028 if the work continues to hold up.
These examples matter because biotech isn't only done at the bench. Coordination, documentation, and decision preparation take up scarce time, especially in smaller organizations. But efficiency alone doesn't make a weak scientific hypothesis stronger. The business case depends on whether saved time leads to better experiments, more informative decisions, or more programs that can be advanced responsibly.
What are the limits and risks of AI-led drug development?
The clearest limit is the stage of evidence. Anthropic describes this work as early and mostly preclinical. Lab findings and animal results can justify further research, but they don't establish safety or effectiveness in humans. Drug candidates can still fail in clinical trials even after promising preclinical results. So the reported numbers should be treated as early, project-specific outcomes - not proof that AI has raised the overall success rate of drug development.
A second limit is that model output is only as useful as the process around it. In BigHat's case, the team concluded that commonly used measurements might not reflect the properties they were trying to optimize. Reanalyzing raw data and changing the protocol helped test that concern. That kind of scientific back-and-forth is essential: AI can accelerate a flawed measurement just as easily as it can accelerate a good one.
There are also governance issues. Drug development involves sensitive research and business information, and clinical planning decisions can be expensive and consequential. BMS emphasized securing its proprietary data. Teams adopting these systems need to define who can access information, how outputs get checked, what gets recorded, and who remains accountable for decisions. Model fluency is not a substitute for provenance and review.
Finally, biological capabilities can be dual-use. Tools that support legitimate research can also raise misuse concerns. Anthropic says its Life Sciences Verification Program lets trusted organizations access its most powerful models with more permissive safeguards. That reflects a real trade-off: controls shouldn't block valid research unnecessarily, but expanded access needs a clear basis for trust and monitoring.
For a biotech team, a practical evaluation should include:
- A defined task: Specify what the model will do, and what scientists or clinicians must still own.
- A measurable baseline: Compare time, error rates, or experimental outcomes against the current workflow.
- Independent validation: Check outputs using experiments, source records, or expert review - rather than relying on convincing text.
- Failure handling: Decide how to escalate uncertainty, incorrect outputs, and conflicting evidence.
- Data and access controls: Match permissions and safeguards to how sensitive - and how risky - the work is.
The goal isn't to remove human judgment. It's to put human expertise where it actually changes the outcome: choosing meaningful questions, validating evidence, and making decisions you can stand behind.
What comes next for AI in medicine?
Anthropic says it plans to expand work with drug developers and move further into clinical research as programs advance. That means testing whether Claude can support trial design and related decisions, not just preclinical discovery or operational tasks. The company also says it wants to work with organizations whose programs are already at the clinical stage.
Alongside partnerships, Anthropic has launched Claude Science, an AI workbench for researchers, and offers Claude credits for life scientists. It has also opened a call for guest investigators proposing work on drug discovery and related life-sciences questions. The strategy here seems to be distribution: make models available to more researchers, then use partnerships and verification processes to learn where access needs more safeguards.
For the wider industry, the most useful evidence next will be less about how many designs a model can generate and more about whether AI improves an end-to-end development workflow. Does it help teams choose better experiments? Can they reproduce the results? Does it reduce delays without adding review burden or increasing risk? Do programs move forward because the underlying evidence is stronger?
Answering those questions will require longitudinal evidence across diseases, teams, and development stages. The early case studies suggest AI can contribute to specific tasks and produce measurable results in some settings. They don't yet show that these improvements translate into more successful medicines. That distinction should shape both investment decisions and public claims.
Conclusion
The early Claude projects give a grounded look at where AI may fit in drug development: beyond molecular design, it shows up in lab optimization, documentation, day-to-day operations, and clinical planning. Some reported gains are substantial, but they're still tied to early projects, and they haven't yet shown better medicines in people.
For biotech teams, the practical path is to start with a real bottleneck, set a measurable baseline, and keep outputs tied to experimental results or expert validation. AI is worth adopting when it improves the quality or speed of decisions without hiding uncertainty, weakening controls, or shifting accountability away from the people doing the work.